Key Takeaways

Coherus is raising ~USD 50 million at $1.75 per share, diluting existing shareholders but funding critical commercialization of LOQTORZI.
The pricing sits near a 12‑month low, hinting at upside if clinical milestones hit.
Sector‑wide capital inflows into immunotherapy suggest a supportive macro environment.
Peers such as Tata Biotech and Adani Health are either expanding pipelines or securing strategic partnerships, increasing competitive pressure.
Historical biotech fundraises at similar valuations have delivered 30‑70% post‑offering rallies when data readouts were positive.

You missed the early warning sign on Coherus’s latest capital raise.

On February 12, Coherus Oncology announced a priced, underwritten public offering of 28.6 million common shares at $1.75 each. The gross proceeds—about $50.1 million before underwriting discounts—are earmarked for scaling the commercial rollout of LOQTORZI® (toripalimab‑tpzi), advancing two mid‑stage candidates, and shoring up working capital. The offering also carries a 30‑day over‑allotment option (often called a “green‑shoe”) for an additional 4.29 million shares, giving underwriters the ability to stabilize the share price if needed.

What the $1.75 Per Share Offering Means for Coherus’s Balance Sheet

The infusion lifts cash reserves from roughly $15 million to an estimated $65 million, a 4‑fold increase that dramatically improves liquidity ratios. Current assets will surpass current liabilities, moving the company into a comfortable current‑ratio zone (>1.5). This cash runway extends the commercial phase of LOQTORZI for at least 18‑24 months, covering manufacturing, marketing, and reimbursement activities in key Asian markets where nasopharyngeular carcinoma incidence remains high.

However, the dilution effect cannot be ignored. Existing shareholders will see their ownership percentage drop by about 11‑12%, and the post‑offering market cap will be roughly $120 million (assuming a post‑offering price close to the offering price). The key question for investors is whether the incremental revenue from LOQTORZI and the pipeline can generate earnings per share (EPS) growth that outweighs the dilution.

Sector Momentum: Why Cancer‑Immunotherapy Is Attracting Capital

Immuno‑oncology remains one of the fastest‑growing therapeutic categories, with global sales projected to exceed $200 billion by 2030. Checkpoint inhibitors, particularly PD‑1 blockers, dominate the market, and newer agents that claim superior efficacy or safety are prized by both payers and patients. The FDA’s recent “accelerated approval” guidance for combination regimens has spurred a wave of partnership deals, creating a fertile environment for companies like Coherus to raise equity at attractive valuations.

In the past 12 months, the average price‑to‑sales (P/S) multiple for listed immunotherapy firms has hovered around 15‑20×, compared with a broader biotech average of 8‑10×. This premium reflects investor belief that successful PD‑1 candidates can quickly become cash‑generating “blockbusters.” Coherus’s LOQTORZI, already approved in China for recurrent/metastatic nasopharyngeal carcinoma, is positioned to leverage this premium if it can secure approvals in additional indications such as head‑and‑neck or colorectal cancer.

Peer Comparison: How Tata’s Biotech Arm and Adani’s Health Venture Are Positioning Themselves

Tata Biotech, a subsidiary of the Tata Group, recently closed a $70 million equity raise to fund a CAR‑T platform aimed at hematologic malignancies. While their focus is on cell therapy—a higher‑cost, higher‑risk modality—both firms share a reliance on partnerships for global market access. Tata’s raise was priced at $2.10 per share, indicating a marginally higher market confidence, but the capital will be spread across multiple programs, diluting the impact on any single candidate.

Adani Health, part of the broader Adani conglomerate, announced a strategic acquisition of a niche checkpoint inhibitor developer for $85 million in cash, financed partly through a revolving credit facility. Unlike Coherus, Adani is leveraging debt rather than equity, preserving shareholder dilution but increasing leverage ratios. The move underscores a divergent financing strategy: Adani bets on balance‑sheet strength to fund rapid pipeline expansion, whereas Coherus chooses equity to avoid debt‑service constraints.

The juxtaposition highlights an investment theme: companies with clear, near‑term commercial pathways (Coherus) may favor equity to stay cash‑positive, while those pursuing longer‑horizon, high‑cost technologies (Tata, Adani) blend debt and equity to manage risk.

Historical Precedent: Past Oncology Fundraises and Their Stock Impact

Looking back, three notable biotech IPOs/secondary offerings provide a template:

Gilead’s 2014 Hepatitis‑C acquisition financing: Raised $1.2 billion at a 20% discount to market price; shares rallied 45% within six months after positive Phase III data.
Bluebird Bio’s 2021 secondary offering: Priced at $16 per share (a 30% discount). The stock fell 25% post‑offering but recovered once the gene‑therapy data showed durable responses.
Moderna’s 2022 capital raise: $1.34 billion at $115 per share, marginally above market. The infusion funded mRNA pipeline diversification and the stock climbed 60% over the following year.

The common thread is that when capital is deployed toward a clear commercial product and the company hits key data milestones, the dilution is more than compensated by upside in valuation. Coherus’s situation mirrors Gilead’s case, albeit on a smaller scale.

Technical Corner: Understanding Underwritten Offerings and Green Shoe Options

An underwritten offering means investment banks (here TD Cowen, Guggenheim, and Oppenheimer) guarantee to buy any unsold shares, providing price stability and certainty of proceeds. The green shoe (over‑allotment) option allows underwriters to purchase up to 15% more shares at the offering price, which can be exercised if demand exceeds supply, helping to prevent a post‑offering price drop.

For investors, the presence of a green shoe is a subtle bullish signal: underwriters anticipate enough market appetite to absorb extra shares without depressing the price.

Investor Playbook: Bull vs. Bear Cases

Bull Case

Successful commercialization of LOQTORZI in China drives top‑line revenue of $30‑$45 million in FY 2027.
Positive Phase II data for Tagmokitug (anti‑CCR8) unlocks combination trials with LOQTORZI, attracting partnership cash (potential $150‑$200 million).
Sector P/S multiples stay elevated, pushing Coherus’s valuation to 20× sales, implying a market cap of $250 million—over 100% upside from post‑offering levels.

Bear Case

Regulatory setbacks or delayed reimbursement approvals in key Asian markets stall LOQTORZI revenue.
Pipeline candidates fail to meet efficacy thresholds, forcing write‑offs and eroding cash runway.
Broader biotech market correction compresses P/S multiples to 8‑10×, leaving the stock undervalued relative to cash burn.

Ultimately, the decision hinges on your risk tolerance and view of the immunotherapy macro‑trend. If you believe the sector’s growth story remains intact and Coherus can convert its cash infusion into meaningful sales, the offering price may represent a discount to future value. If you doubt the company’s ability to navigate regulatory and commercial hurdles, the dilution may be a red flag.

Why the Thai Baht's Surge Could Flip Your Asia Portfolio: Risks & Rewards